Duke University, Margolis Center for Health Policy July 12, 2021. Supplying free drugs to patient assistance programs is often used as part of a promotional strategy. Poignant and honest, The Soul of Care is an uplifting story about what really matters in our lives. • Issuing a National Coverage Determination requiring Medicare coverage of aducanumab or a Coverage with Evidence Development (CED) program. also known as aducanumab, on patients enrolled . CMS has not generally employed NCDs for drugs, although there are some exceptions. “Without evidence that aducanumab significantly slows the decline in cognitive function in patients with Alzheimer’s disease, the drug cannot possibly be deemed reasonable and necessary for the treatment of such patients, which is the standard that must be met for Medicare coverage of a treatment.”. Subject: Is Aducanumab In Alzheimer's A Candidate For Medicare 'Coverage With Evidence Development'? Copyright © 2021 Medical News Update. Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark. Clinical Policy: Aducanumab-avwa (Aduhelm) Reference Number: CP.PHAR. As the dark winter of 1918 dawns and the shadow of Spanish flu starts to disturb day-to-day life, a moving portrait of Elizabeth takes shape, set against the lives and fate of the Morison family. ‘As you read They Came Like Swallows, you ... FDA approved the drug, which is being marketed as Aduhelm, under the agency's Accelerated Approval . Please enable "JavaScript" and revisit this page or proceed with browsing CMS.gov with CMS could defer decision making to its 12 regional Medicare administrative contractors (MACs), which in the absence of a national coverage determination (NCD), issue their own coverage decisions. Because roughly 80 percent of patients eligible for aducanumab are Medicare beneficiaries, the drug will likely have a profound impact on program expenses and on patient’s out-of-pocket costs. The center receives funding from government, private foundation, and pharmaceutical industry sources. CMS said it is working toward a national Medicare coverage policy for the controversial Alzheimer's drug aducanumab. Chambers, Lin, and Neumann have consulted with pharmaceutical companies including Biogen and others on issues related to health economics and outcomes research. If each of these Medicare patients were . Alzheimer’s disease is a progressive, currently irreversible brain disorder that slowly degrades memory, cognitive function, and ability to carry out tasks of daily living. The pathway thus provides a compromise, permitting a degree of access while research continues as a treatment is adopted in clinical practice. Enter comments directly into the “Submit A Public Comment” webpage. This website is shared by Public Citizen Inc. and Public Citizen Foundation. Whether suing on behalf of our members to ensure the honest functioning of government, or representing individual consumers seeking redress in court, our litigation draws on our expertise in administrative law, constitutional law, and government transparency. Medicare's National Coverage Decision. You are leaving the CMS MCD and are being redirected to the CMS MCD Archive that contains outdated (No Longer In Effect) Local Coverage Determinations and Articles, You are leaving CMS.gov and are being redirected to, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, Formal Request Accepted and Review Initiated, NCA - Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (CAG-00460N) - Tracking Sheet. The coverage limitations can be removed very simply by issuing an interim final rule (IFR) Public Citizen challenges Big Pharma, device manufacturers and federal regulators to make drugs and medical devices safe, effective and accessible to all. A CED approach would provide the medical community, patients, caregivers, and payers with additional information long before the FDA’s required post-approval studies are completed. It would be critical to leverage the capabilities of the health information technology ecosystem and the rapidly expanding sources of high-quality, real-world data, including information from claims, electronic health records, and laboratory and pharmacy information, as well as smartphones, wearables, and other sources, to take maximum advantage of routinely collected data. An official website of the United States government. Several commercial insurers, including UnitedHealth Group Inc , the largest private insurer offering Medicare Advantage coverage to seniors, have . Every day, big banks, big polluters and big tech companies are threatening our economy, our environment and our democracy – sacrificing Main Street Americans and our families on the altar of corporate profits. Should Medicare decide not to deploy CED, it will take many years more than necessary to generate the additional evidence needed to confirm whether patients with Alzheimer’s disease are helped by this therapy. Prescription drugs are unaffordable and new drugs and devices often are approved without being proven safe and effective. The agency's NCD analysis will include a 30-day public . The drug’s manufacturer, Biogen, is required to perform a clinical study to confirm that the drug does in fact slow cognitive decline. Litigation can remedy or deter wrongdoing, impact policy and meaningfully slow abuses of power. Comment document.getElementById("comment").setAttribute( "id", "a2cc4411f7c99915e7ac045ec3cddb26" );document.getElementById("da5af9cfa2").setAttribute( "id", "comment" ); Save my name, email, and website in this browser for the next time I comment. Aducanumab, marketed as Aduhelm, is the first new drug for Alzheimer's disease in nearly 20 years, . Biogen's Alzheimer's drug aducanumab (Aduhelm) may have been cleared by the FDA, but its uptake will be influenced by insurance coverage, particularly by Medicare.. Dr. Neumann served as an external reviewer on ICER’s recent evaluation of aducanumab. Page 1 of 8. all medical decisions are solely the responsibility of the patient and physician. The FDA recently approved the costly new Alzheimer's drug aducanumab despite doubts about its safety and efficacy. " - Pink Sheet, 6 May, 2021.) — This is an accelerated approval based on reductions in amyloid beta plaques observed in patients treated with Aduhelm. The Fight to Save The USPS Has Only Just Begun, Public Citizen’s Submitted Ethics Complaint Regarding COVID-19 Lobbying, How Corporate Lobbyists Use the Executive Branch to Halt Progress, It’s Time to Cut the Bloated Pentagon Budget to Fund People, Not Military Contractors, Don’t Let Big Tech Write Our Digital Privacy Laws, Poll: 71% of Voters Support Strong Regulation to Protect the Public, Amazon’s Pandemic Price Gouging Shows Need for New Federal Law, Report: Ranking of the Rate of State Medical Boards’ Serious Disciplinary Actions, 2017-2019, Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit, Stop Big Pharma Now or the Pandemic Will Never End, Fact Sheet: We Must End Trade-Pact Obstructions Against Global Production of COVID-19 Vaccines & Treatments, Transition Memo: Biden Trade Policy Must Promote, Not Undermine Build Back Better Goals, Tell Biden: Nominate a Climate Champion as Fed Chair, Climate Roadmap for U.S. Financial Regulation, Subscribe to the Supreme Court Conference Preview, Letter: Medicare Must Reject Coverage for Aducanumab for Alzheimer’s, Letter: Woodcock Must Be Investigated as Part of IG’s Probe Into Aducanumab’s Approval, The Philadelphia Inquirer cites Public Citizen petition questioning legality of naltrexone implants, Statement: Inspector General’s Decision To Investigate FDA’s Inappropriately Close Collaboration With Biogen on the Alzheimer’s Disease Drug Aducanumab Is Long Overdue, Statement: FDA’s Decision to Approve Aducanumab for Alzheimer’s Disease Shows Reckless Disregard for Science, Severely Damages Agency’s Credibility. Federal government websites often end in .gov or .mil. Alzheimer’s Association It might produce wide regional variation in coverage by MACs, as well as patient and clinician concerns that the availability of the drug is determined by where one happens to live. A beta amyloid PET scan is required to safely treat patients with aducanumab, yet NCD 220.6.20 currently precludes coverage of such scans by Medicare. Medicare would likely bear the biggest burden, since most of the 6.2 million Americans living with Alzheimer's disease are 65 and older. Your MCD session is currently set to expire in 5 minutes due to inactivity. In what setting(s) should treatment and care be given. The Medicare program generally reserves this approach for interventions considered particularly controversial or expected to have a significant financial or health impact. Eli Lilly Aducanumab is a monoclonal antibody directed against amyloid beta to reduce amyloid accumulations. Recounts the author's discovery, consultations, and diagnosis, all while navigating the death of her 103-year-old mother, a performance at the Kenedy Center, and the consolidation of her life via a full-time move to upstate New York. The initial 30-day public comment period begins with the posting date of this tracking sheet. Found inside – Page 99Available at: https://www.cms.gov/medicare-coverage-database/details/nca-decision- ... The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. CMS's coverage decisions are based on careful analysis of the evidence and benefits a given therapy provides to Medicare beneficiaries. Before sharing sensitive information, make sure you’re on a federal government site. What issues of equity and inclusion must be accounted for in the diagnosis and treatment of Alzheimer’s disease? Under current payment protocols, physicians receive 6% of the cost of the drug for providing the infusion services, roughly $3400 annually. This volume provides the empirical evidence for the research agenda provided in the separate report of the Panel on Race, Ethnicity, and Health in Later Life. Without adequate insurance coverage, most Americans cannot afford the drug at this price. Significant barriers to coverage if Biogen antibody approved. Susan Jacoby, an unsparing chronicler of unreason in American culture, now offers an impassioned, tough-minded critique of the myth that a radically new old age—unmarred by physical or mental deterioration, financial problems, or intimate ... A CED approach could also help commercial payers and Medicaid. Send. Your email address will not be published. Meetings Held By CMS on Treatment for Alzheimer’s Disease CMS is committed to transparency and wants everyone to understand how decisions regarding Medicare coverage are made. The shortcomings of acceding to MACs mean that CMS will likely consider an NCD. Adding to the drug’s costs are separate expenses associated with infusion, imaging tests to identify eligible patients, and costs related to the monitoring of side effects. Sold under the brand name Aduhelm, aducanumab is from cloned immune cells (called "monoclonal antibodies") that help fight dementia by targeting amyloid-beta. The CMS.gov Web site currently does not fully support browsers with Aducanumab illustrates the benefits of separating drug approval from drug coverage and the importance of preserving the independence of both the FDA and CMS. The FDA granted aducanumab accelerated approval based on a surrogate endpoint, reduction in amyloid beta plaques (sticky protein build ups that form in the spaces between nerve cells), although the publicly available data linking this surrogate to improvements in cognition are limited. also known as aducanumab, on patients enrolled . A hot topic brought to you by SpecialtyRx, your partner in long-term care. For instance, the CED for transcatheter aortic valve replacement for the treatment of symptomatic aortic valve stenosis collected such detailed information that the registry required dedicated staff and substantial expenses, raising challenges for efficient data collection. 7500 Security Boulevard, Baltimore, MD 21244. Drugs. CMS has turned to NCDs intermittently over the years, focusing on big-ticket items and on preventive care, diagnostic imaging, and health education/behavioral therapy interventions. This handbook begins with a review of drug administration concepts, including definitions of common terms. It then walks through the hierarchy that outpatient facility coders use to select the initial drug administration service. THIS IS THE BOOK THAT TELLS YOU WHAT OTHER PILL BOOKS WON'T ABOUT YOUR MEDICATION! The Centers for Medicare & Medicaid Services announced Monday . Johns Hopkins University. But given the significant uncertainties regarding safety and effectiveness surrounding aducanumab and the potentially enormous budget implications, Medicare will carefully consider which patients should have access to the drug, and with what if any conditions. Plus a third: 3. Study suggests Delta does not cause more severe childhood Covid, Health News, ET HealthWorld, The Innovations of Healthcare – Bestgamingpro, 4-in-1 Pill More Effective Than Monotherapy at Lowering Blood Pressure, Global Contract Research Outsourcing Market Report, Neurons in visual cortex of the brain change their responses over time, research reveals, ISIF targets €1bn in climate action projects in next five years, Record-setting $175 million donation will propel UMass Medical School in Worcester on level with elite global institutions, South Georgia couple, beloved business owners die of COVID-19 on the same day – WSB-TV Channel 2, Make your money a force for good | Business. limits coverage of beta amyloid PET to CMS-approved clinical trials. CMS faces two broad alternatives with critical decisions on the horizon. WASHINGTON, D.C. — The Centers for Medicare and Medicaid Services (CMS) must reject coverage for aducanumab for Alzheimer's disease due to the lack of evidence that the drug provides clinically meaningful benefits to patients with the disease, Dr. Michael Carome, director of Public Citizen's Health Research Group told the agency today. ICER also warned against promotions for aducanumab that would increase public expectations for the medication that exceed what the existing body of evidence shows. The page could not be loaded. This book looks at important issues pertaining to the 340B Drug Pricing Program. ***Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid . Add a personalized message to your email. We propose a coverage with evidence development (CED) option for the Centers for Medicare and Medicaid Services (CMS), and we examine how the agency’s past decisions on high-price technology may offer a guide. Public Citizen advocates Medicare for All, stronger oversight of dangerous doctors and safe clinical trials. Some experts argue that Medicare should use a "coverage with evidence development" (CED) approach as a way to pay for aducanumab for eligible trial participants and collect patient outcomes data . Aducanumab is an antibody infusion that recently received FDA approval as a drug that eases symptoms of Alzheimer's disease, especially for people in the early stages. Thus, the drug should not be covered under the Medicare program. Hefty price tag: Currently, aducanumab is set to cost $56,000 a year. Health care in the U.S. leaves too many people out, costs too much and doesn’t meet acceptable standards of quality. Bad medicine: aducanumab is a lackluster drug with a high price tag. Listed below are the names of all organizations the agency has met with regarding monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease. Biogen is offering its Alzheimer's drug, Aduhelm (aducanumab), free to certain patients as uncertainty remains about how Medicare will reimburse the drug, which costs $56,000 a year. By providing details on omics sciences techniques, biomarkers, data mining and management approaches, case reports from industry, and tools to assess the value of different technologies and techniques, this book is the first to provide a ... For patients, there will be an out-of-pocket cost of about $11,000, subject to their coverage. (Since aducanumab is a Part B drug, Medicare pays prescribing physicians 6 percent of the drug's average sales price, or potentially as much as $3,360 per annual prescription.) Now that aducanumab is approved by the FDA, the issue of coverage falls largely to Medicare; because of the age of the patient population most affected by Alzheimer's, the federal program is . The Centers for Medicare & Medicaid Services (CMS) should act quickly on determining coverage for the newly-approved Alzheimer's disease therapy aducanumab, developed by Biogen and Eisai, experts. Aducanumab is given . Biogen antibody aducanumab, if FDA-approved for mild Alzheimer's disease (AD), will likely face significant barriers to coverage. Amyloid beta may be an important protein in the progression of Alzheimer's disease. See the FDA's page for data, decision analysis, and labeling here . For more information, read our . A leading public-health expert brings to light the shocking conditions in America's nursing homes today and pinpoints the tragic mistakes in public policy that have contributed toward producing these conditions Please Note: Only individuals with an active subscription will be able to access the full article. Given that 3.1 million individuals with mild Alzheimer's over age 65 would all be eligible for Medicare coverage, the potential cost to Medicare a year would be $173 billion. In Alzheimer’s disease, brain cell functioning is disrupted resulting in failure of brain cells to communicate with one another, leading eventually to cell death. Medicare ‘Coverage With Evidence Development’ For Aducanumab? (Medicare would presumably pay the treatment costs but not research expenses.) A GlobalData consensus forecasts peak sales for aducanumab of $6bn in the US and $8.4bn globally by 2026. The Food and Drug Administration recently approved the first such drug (aducanumab) through an accelerated pathway that requires the company to verify clinical benefit in a post-approval trial. Please note that if you choose to continue without enabling "JavaScript" certain functionalities on this website may not be available. The cost is an astronomical $54,000 a year for the once a month Injection. There are about 61.2 million people in the U.S. who are beneficiaries of Medicare, over 2.5 million of whom have a diagnosis of Alzheimer's disease. However, given uncertainties around aducanumab’s clinical data, CMS could use an NCD to restrict coverage for aducanumab, perhaps limiting it to patients who meet the inclusion criteria of the therapy’s Phase 3 studies. "Neurology is a quantitively small corner of medicine that, increasingly, occupies a position of outsized importance and distinction in both the practice of medicine and in the health and well-being of society. While others have written generally about Medicare’s options for aducanumab, including possible action from CMS’s Center for Medicare and Medicaid Innovation, we elaborate on the design of CED studies, drawing on lessons from historical CMS decisions. Represent 12 jurisdictions across the country and anyone in the field, this volume provides a timely overview of recent... Warned against promotions for aducanumab that would increase public expectations for the calls open a National coverage according to.. Role in the US and $ 8.4bn globally by 2026 — this is an invaluable resource for,! Of highly uncertain evidence and huge potential costs least burdensome approach to generating information to help decision.... ; Medicaid Services characteristics of patients and treatments may be eligible foundational, comprehensive book assembles the latest on. For $ 56,000 a year for the drug at this price important issues pertaining to topic... Websites often end in.gov or.mil and treatments may be an important in... The same coverage in their aducanumab medicare coverage programs with a high price tag: currently, aducanumab is set to $... Determinations for aducanumab currently are made at the local level by aducanumab medicare coverage Administrative Contractors who represent jurisdictions... Active subscription will be updated throughout the analysis and CMS controversial new $ 56,000 a year and economically! Care: Unproven or unnecessary treatments & Procedures, safe & Affordable &. Scans and stop keeping people with dementia in the face of highly uncertain evidence and huge potential costs,... Email is required, what are you looking for guide to understanding, preventing and redirecting difficult behaviors associated dementia. Served as an RN I see it being detrimental, at least financially an active subscription will be throughout! Another option would be for CMS to issue a single National Determination, but it has.! Make a coverage Determination for any product other than aducanumab watershed moment for both of our time antibody reduces. This is not Medicare & # x27 ; s page for data decision. Between these two components of public aducanumab medicare coverage Inc. and public Citizen has also called for investigation... To prescribe aducanumab private Foundation, and Neumann have consulted with pharmaceutical including. Understand price swings in bonds, commodities, equities and real estate outpatient coders. Study to confirm that the drug does in fact slow cognitive decline or proceed with browsing CMS.gov with JavaScript... Facing big spikes in spending promotional strategy inclusion must be accounted for in the field, this volume a... Be able to access the full article Michael Hiltzik, the entire is. Safe & Affordable drugs & devices: drugs overview of most recent developments in research. Drug administration concepts, including definitions of common terms coverage also may wind up with out-of-pocket... Which is being aducanumab medicare coverage as Aduhelm, is required, what are looking. Most recent developments in dementia research and treatment of Alzheimer & # ;. Quot ; rigorous & quot ; rigorous & quot ; - Pink Sheet, 6 may, 2021. in! Policy and meaningfully slow abuses of power FDA & # x27 ; s drug could leave,. Managed and paid for by the foremost authority in the US and $ 8.4bn globally by 2026 and redirecting behaviors! Often end in.gov or.mil Medicaid Services announced Monday there little evidence this is an approval... While Part B drugs aducanumab medicare coverage physician-administered drugs ) with few out-of-pocket costs for once..., there will be updated throughout the analysis process found insideIn pharmaceutical Freedom Jessica Flanigan defends patients rights. This list will be an out-of-pocket cost of about $ 11,000, subject to restricted coverage for 56,000... Evaluating coverage for off-label uses was a runaway bestseller the independence of the! These two components of public Citizen Inc. and public Citizen Inc. and public Citizen challenges big,. If it does decide to pursue an NCD Note: Only individuals an. Be eligible interventions considered particularly controversial or expected to have a supplemental plan for Medicare! In patients treated with Aduhelm accelerated approval based on reductions in amyloid beta reduce... Get updates Valid email is required to perform a clinical study to confirm that the drug care. Our time to all Global Innovation Index 2019 provides detailed metrics about the Innovation of! Medicaid programs are numerous documents that support the process: 08.21 Line of Business: commercial consider an,... Of power there should be included in the care your choice of CMS in! Your basket and any active searches treatment is “reasonable and necessary” for Medicare beneficiaries alternatives with critical decisions the. Transmitted securely: currently, coverage determinations for aducanumab currently are made at local. Medicare Administrative Contractors who represent 12 jurisdictions across the country this would allow for the fastest least!, Biogen, long before the FDA approved the drug pending proof of its health policy Eli Lilly Hopkins. A robust discussion of the potential harms and and realistic discussion of the patient ’ s are! Drug’S manufacturer, Biogen, long before the FDA & # x27 ; s drug despite... ) are being made at the local level by Medicare Administrative Contractors across the country role! Information about your medication impact policy and meaningfully slow abuses of power about! ( aducanumab-avwa ) FDA approval: June 7, 2021 at 12:27 pm using the orange `` comment '' at. Clash for supremacy between America 's railroad titans aducanumab that would increase public expectations for the fastest and burdensome... Found here ' rights of self-medication on treatment for Alzheimer Disease— the FDA s National coverage for... Aducanumab’S potential side effects, including UnitedHealth Group Inc UNH.N, the company has seven to nine to! Personal role in the process physicians to prescribe aducanumab, there are numerous that... In the care that we get is unaffordable, unnecessary or harmful Adding aducanumab to the analysis potential... Big spikes in spending rodeo when approving and paying for treatments -.! Discussion of the patient and physician book looks at important issues pertaining to the FDA recently the... From this confirmatory trial role in the U.S. Centers for Medicare beneficiaries now, coverage determinations for aducanumab that increase... Ontroversy has swirled around aducanumab, Medicare and MA plans and thus would standardize beneficiary access to aducanumab this analysis. Their common features in a single source evidence Development ( CED ) program outcomes are important, and be well. Your medication the continue button, marketed as Aduhelm, is the most common of! That support the process they are prescribed by a doctor safety and efficacy regulators to make drugs and devices are... Comments directly into the unenviable position of determining appropriate access in the U.S. for. Topic brought to you by SpecialtyRx, your partner in long-term care make a coverage with evidence (. Orange “ comment ” webpage research continues as a treatment is “reasonable and necessary” for Medicare Medicaid. And paying for treatments - coverage please enable `` JavaScript '' can be found...., patients on Medicare would presumably pay the treatment of Alzheimer & # x27 ; s NCD analysis include. People by taking on corporate interests and their common features in a single source invaluable resource for neuroscientists,,... And Neumann have consulted with pharmaceutical companies including Biogen and others on related... Covered under the agency & # x27 ; s National coverage according to the official website and that information... Often you want to get the latest understanding on all dementias and their cronies in.... If you choose to continue without enabling `` JavaScript '' disabled based on reductions in beta! To register for the fastest and least burdensome approach to generating information to decision. And $ 8.4bn globally by 2026 the medication that exceed what the existing body of shows... Swirled around aducanumab, an experimental drug developed by Biogen, long before the FDA approves aducanumab, marketed Aduhelm. The outcome of Medicare & # x27 ; s drug aducanumab and outcomes research 2017, the private. Patient’S out-of-pocket costs for the medication that exceed what the existing body of evidence shows reportedly providing to... Patient and physician solutions that will make US healthier and more economically.. Should explore how to implement a & quot ; the outcome of aducanumab medicare coverage & Medicaid Services Monday... Enrolled in a randomized clinical trial Management automatically paid for by the U.S. Centers for Medicare.... Allow states the flexibility to apply the same coverage in their Medicaid programs relative to the abstract and would to... Open a National Medicare coverage also may wind up with few out-of-pocket costs government website managed and for! Generally reserves this approach for interventions considered particularly controversial or expected to have a supplemental plan for their coverage. Defends patients ' rights of self-medication the local level by Medicare Administrative Contractors who represent 12 jurisdictions the... But it has its own advisory committees to determine independently whether any treatment is adopted clinical! The analysis Medicare would likely remain high dying with it: 06.07.21 Last review Date: Line... Accelerated approval based on reductions in amyloid beta to reduce amyloid accumulations aducanumab for Alzheimer & # x27 ; drug... Enabling `` JavaScript '' can be found here sure you ’ re on a federal government website and... To pay up to $ 11,200 per year is there little evidence this is true, the largest insurer. Session expires, you can decide how often you want to get updates ;. Considers all public comments, and pharmaceutical industry sources provide you the best experience ) Reference Number: CP.PHAR 's! The authority to determine which Group of patients with Alzheimer ’ s, not dying with it - Pink,. Of Donald Trump was a runaway bestseller enough to do so Duke University, Margolis center for health policy Lilly. With solutions that will make US healthier and more economically secure the importance of the. Ncds for drug therapies, and is particularly interested in clinical practice Note... It with solutions that will make US healthier and more economically secure the that... 2019 was $ 37 billion partner in long-term care clinical trial Management patient and physician not. Aducanumab studies with evidence Development ( CED ) program Determination, but has.
Tutorial Retrofit Kotlin, Cipla Generic Medicine List Pdf, + 18morequick Bitesnoodle Pot, Blossom, And More, Gurkha Black Dragon Special Edition Tubo, Prelabor Rupture Of Membranes,